MASSDEVICE ON CALL — Robot-assisted procedures are making up an ever greater portion of hysterectomies, but researchers aren’t sure that the extra cost leads to better outcomes.
Women's Health
Breast cancer: Dune Medical wins EU nod for next-gen tissue screening system
Dune Medical Devices won European regulatory approval for the latest generation of its breast cancer detection tool, the MarginProbe System Type 1.2 console.
Women’s health: Halt Medical lands Mexican win for uterine fibroid treatment
Women’s health devices maker Halt Medical touted a win from Mexican healthcare regulators who granted registration for the Acessa System for treating uterine fibroids.
The Acessa technology represents a major shift in treatment of uterine fibroids, the company has said. Fibroids are the leading global cause of hysterectomy procedures, according to the Centers for Disease Control & Prevention.
Conceptus hits 52-week high on swing to Q4, 2012 black
Breast cancer: Judge stays C.R. Bard suit against Hologic over Mammosite device
Hologic’s fiscal Q1 profits dive on Gen-Probe acquisition costs
Patient takes the stand in Johnson & Johnson mesh lawsuit | MassDevice.com On Call
MASSDEVICE ON CALL —Plaintiff Linda Gross took the stand this week in a bellwether trial against Johnson & Johnson (NYSE:JNJ) subsidiary Ethicon’s transvaginal mesh implants.
Layoffs: Hologic to shutter Indiana plant
Hologic (NSDQ:HOLX) said it plans to shutter a breast biopsy device-making plant in Indianapolis this summer, laying off all 141 workers at the facility.
The closure will roll out in 4 phases, beginning with layoffs for 20 workers March 29, according to a letter sent to the Indiana Dept. of Workforce Development from the Bedford, Mass.-based women’s health company.
MassDevice.com +3 | The top 3 med-tech stories for Jan. 15, 2013
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
Juror selection begins for Johnson & Johnson transvaginal mesh lawsuits | MassDevice.com On Call
MASSDEVICE ON CALL — A bellwether trial against Johnson & Johnson (NYSE:JNJ) began this month with lawyers beginning to select jurors to hear a lawsuit accusing the healthcare giant of liability patient injuries allegedly caused by the company’s transvaginal mesh implants.
Funding: Halt raises $15M to commercialize its device to treat uterine fibroids
Halt Medical closed a $15 million funding round from American Capital, aimed at commercializing its FDA-cleared Acessa System for treating uterine fibroids.
The Las Vegas, Nev.-based device maker said its Acessa system allows physicians to deliver radiofrequency energy to uterine fibroids through a minimally invasive procedure.